Study identifier:D3060C00003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A randomised, double-blind, placebo and active controlled, multi-centre, 6 way cross-over, single-dose Phase IIa study to investigate the local and systemic effects of 3 different doses of inhaled AZD2115 in patients with chronic obstructive pulmonary disease (COPD)
COPD
Phase 2
No
AZD2115, Placebo, Indacaterol, Indacaterol + Tiotropium
All
39
Interventional
40 Years +
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Oct 2012 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Single dose of AZD2115 25 µg | Drug: AZD2115 AZD2115 administered via inhalation |
Experimental: Single dose of AZD2115 80 µg | Drug: AZD2115 AZD2115 administered via inhalation |
Experimental: Single dose of AZD2115 240 µg | Drug: AZD2115 AZD2115 administered via inhalation |
Placebo Comparator: Single doses of placebo | Drug: Placebo Placebo administered via inhalation |
Active Comparator: Single dose of indacaterol 150 µg | Drug: Indacaterol Indacaterol administered via inhalation |
Active Comparator: Single dose of indacaterol 150 µg + tiotropium 18 µg | Drug: Indacaterol + Tiotropium Indacaterol + Tiotropium administered inhalation |